News und Analysen
![Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development
Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the
![Evotec: Nach Abu Dhabi nun Bill Gates an Bord!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Evotec: Nach Abu Dhabi nun Bill Gates an Bord!
Evotec (WKN: 566480) meldet heute eindrucksvolle News mit Promifaktor. So wird Bill Gates – der Microsoft-Nerd, über den Elon Musk jüngst in Anspielung auf Michael Jacksons Hit "Billie Jean" sagte
![EnWave Announces Normal Course Issuer Bid](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EnWave Announces Normal Course Issuer Bid
Vancouver, B.C., October 19, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave,” or the "Company” - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine-sales
![EnWave kündigt Aktienrückkaufprogramm an](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EnWave kündigt Aktienrückkaufprogramm an
Vancouver, B.C., 19. Oktober 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine
![Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020
Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab accountability, consistency, and transparency
![Epigenomics: Aktie crasht -77% nach US-Schock](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Epigenomics: Aktie crasht -77% nach US-Schock
Die staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services (CMS) lehnt Epi proColon ab. Das geht aus einem vorläufigen Erstattungsvorschlag hervor. Die Schockwellen sind in der E
![Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of the
![Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical
Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales
Qilu Pharmaceutical to receive an exclusive license to develop and commercialize
![IMV Inc. Re-establishes At-the-Market Facility: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=de)
IMV Inc. Re-establishes At-the-Market Facility
IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated October 16
![Charles River Laboratories Adds George Llado to Board of Directors: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=de)
Charles River Laboratories Adds George Llado to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to
![Medigene AG: Drei Poster Präsentationen von Medigene auf dem SITC Annual Meeting](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Medigene AG: Drei Poster Präsentationen von Medigene auf dem SITC Annual Meeting
Planegg/Martinsried (15.10.2020) - Wissenschaftler der Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die
![Medigene AG: Three Medigene poster presentations at SITC Annual Meeting](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Medigene AG: Three Medigene poster presentations at SITC Annual Meeting
Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell
![Premier Inc. Contracts with HHS on Data-Driven Initiative to Improve U.S. Maternal Health : https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVVrRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c242cfb3032e071de8936910a6c2be2320576bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/PR_LogoSpec_-282-29.jpg?locale=de)
Premier Inc. Contracts with HHS on Data-Driven Initiative to Improve U.S. Maternal Health
Premier Inc. (NASDAQ: PINC) today announced a new, two-year, $8 million national partnership with the U.S. Department of Health and Human Services (HHS) Office of Women’s Health to leverage
![Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award
Agilent Technologies Inc. (NYSE: A) today announced that the Agilent Vaya Raman raw material identity verification system has received a 2020 R&D 100 Award in the Analytical/Test category. The
![NeutriSci Enters the Second Highest Grossing Market with New Distribution in the State of Washington](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
NeutriSci Enters the Second Highest Grossing Market with New Distribution in the State of Washington
Vancouver, British Columbia – October 15, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
![NeutriSci betritt mit dem US-Bundesstaat Washington den Markt mit den zweithöchsten Cannabis-Umsätzen weltweit](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
NeutriSci betritt mit dem US-Bundesstaat Washington den Markt mit den zweithöchsten Cannabis-Umsätzen weltweit
Vancouver (British Columbia), 15. Oktober 2020 - NeutriSci International Inc. (TSX-V: NU, OTCQB: NRXCF, Frankfurt: 1N9) („NeutriSci“ oder das „Unternehmen“, ein innovatives
![Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=de)
Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that
![BOIRON : Projected timetable of the next publications and events 2021](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
BOIRON : Projected timetable of the next publications and events 2021
The projected timetable of the next publications and events for the year 2021 is the following one:
Publications Date of publication (after market closing) Information meetings![Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
![Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that a patient has passed away
![Sensorion Obtains €3 Million Loans, Including €2 Million Guaranteed by the French Government (PGE) and €1 Million as RDI Loan Through Bpifrance](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Sensorion Obtains €3 Million Loans, Including €2 Million Guaranteed by the French Government (PGE) and €1 Million as RDI Loan Through Bpifrance
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
![Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNElsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c4d0ef2109eb59269aca9850381b8fb5000d84e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xencor_RGB_fullcolor.jpg?locale=de)
Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster
![Hanger Announces Executive Appointments To Lead Its Patient Care and Products & Services Business Segments](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Hanger Announces Executive Appointments To Lead Its Patient Care and Products & Services Business Segments
Hanger, Inc. (NYSE: HNGR) today announced the promotion and hiring of two senior executives to lead its two business segments, effective Nov. 2, 2020:
-
Regina Weger has been promoted to
![EOS imaging Reports 9-month Revenue up +32% Year-on-year](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
EOS imaging Reports 9-month Revenue up +32% Year-on-year
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![Humana Announces Major Tennessee Expansion, Will Sell Medicare Advantage Plans in 31 More Counties: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana Announces Major Tennessee Expansion, Will Sell Medicare Advantage Plans in 31 More Counties
As part of Humana Inc.’s (NYSE: HUM) major Tennessee expansion in 2021, the leading health and well-being company announced today it is introducing a new Medicare Advantage Health Maintenance